Released Aug 4, 2020, after the close
10-Q filed Aug 4, 2020, 35 days after period end · 0001232524-20-000054
Q2 2020 · 10-Q
Revenue$562.44M$562.44M +5.3% vs Q2 2019+5.2% vs Q1 2020
Net Income$114.80M$114.80M −56.2% vs Q2 2019N/M vs Q1 2020
EPS Diluted$2.06$2.06 −54.8% vs Q2 2019N/M vs Q1 2020
Gross Profit$530,195,000+6.9%
Operating Income$198,126,000−3.0%
Operating Cash Flowderived$182,519,000+22.6%
Free Cash Flowderived$179,829,000+33.3%
Margins · derived
Gross margin94.3%+1.5 pt vs Q2 2019
Operating margin35.2%−3.0 pt vs Q2 2019
Net margin20.4%−28.6 pt vs Q2 2019
What the release said
The release
Same quarter
| Metric | Q2 2020 | Q2 2019 | Q2 2018 | Q2 2017 |
|---|---|---|---|---|
| Revenue | $562.44M | $534.13M | $500.48M | $394.39M |
| Net Income | $114.80M | $261.90M | $92.32M | $105.60M |
| EPS Diluted | $2.06 | $4.56 | $1.50 | $1.72 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Jazz Pharmaceuticals plc · CIK 1232524 · Engraved from SEC EDGAR